JSPR Earnings & Financial Statements
Jasper Therapeutics, Inc.
$0.50
+$0.01(+1.09%)
31
Overall
60
Value
10
Tech
23
Quality
Market Cap
$16.67M
Volume
620.09K
52W Range
$0.32 - $2.69
Target Price
$6.25
JSPR earnings and financial statements: Jasper Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
JSPR Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | $8.30M | $9.00M | - | $9.00M |
| Operating income | -$83.88M | -$76.24M | -$68.86M | -$51.20M | -$36.83M |
| EBITDA | -$74.70M | -$69.87M | -$76.90M | -$50.22M | -$36.46M |
| Net income | -$75.80M | -$71.27M | -$64.47M | -$37.71M | -$30.64M |
| EPS (diluted) | $-3.95 | $-4.89 | $-6.18 | $-10.30 | $-26.90 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $35.78M | $79.90M | $94.89M | $48.36M | $93.65M |
| Total liabilities | $31.63M | $18.23M | $16.45M | $12.22M | $24.14M |
| Shareholders’ equity | $4.15M | $61.67M | $78.44M | $36.14M | $69.52M |
| Cash and equivalents | $28.69M | $71.64M | $86.89M | $38.25M | $84.70M |
| Long-term debt | - | $724.0K | $1.81M | $2.79M | $2.38M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$77.20M | -$62.60M | -$52.07M | -$45.86M | -$24.40M |
| Capital expenditure | $5.0K | -$532.0K | -$267.0K | -$576.0K | -$2.43M |
| Free cash flow | -$77.21M | -$63.15M | -$52.33M | -$46.48M | -$26.83M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | JSPR | $0.50 | +1.1% | 620.09K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Jasper Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW